CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy (original) (raw)

Viral Infections

Bone Marrow Transplantation volume 26, pages 413–417 (2000)Cite this article

Abstract

The incidence, treatment and outcome of CMV interstitial pneumonia (CMV-IP) were reviewed in 139 consecutive allogeneic BMT patients undergoing extended CMV antigenemia surveillance and two different ganciclovir (GCV) strategies to control CMV infection. Nineteen cases of CMV-IP were reviewed, 16 of 63 patients (25.4%) who received early GCV treatment (ET) and three of 76 patients (3.9%) who received pre-emptive (PE) GCV therapy. In the ET group, the median time for occurrence of CMV-IP was 55 (range 36 to 311) days. Two patients had three episodes of CMV-IP recurrences after day +100. CMV-IP-related death occurred in two patients (15.4%). In the PE group, 41 patients received pre-emptive GCV therapy prompted by the appearance of positive antigenemia ⩾2 cells. The median time for the occurrence of CMV-IP was 92 (range 48 to 197) days. Response to therapy was observed when GCV was introduced within 6 days of antigenemia positivity. The use of IVIg in association with GCV did not play a major role in response to therapy. The median time for occurrence of CMV-IP was delayed during PE strategy and the cost-effectiveness of CMV surveillance after day +100 should be investigated in this population. Bone Marrow Transplantation (2000) 26, 413–417.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Shepp DH, Dandliker PS, Miranda P et al. Activity of 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine in the treatment of cytomegalovirus pneumonia Ann Intern Med 1985 103: 368–373
    Article CAS PubMed Google Scholar
  2. Boeckh M, Bowden RA, Goodrich JM et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation Blood 1992 80: 1358–1364
    CAS PubMed Google Scholar
  3. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side-effects of antiviral therapy after bone marrow transplantation Blood 1995 86: 2815–2820
    CAS PubMed Google Scholar
  4. Boeckh M, Riddell S, Cunningham T et al. Increased risk of late CMV infection and disease in seropositive allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T-cell responses Orange Beach, Alabama: 6th International CMV Workshop 1997 (Abstr. 70)
  5. Li CR, Greenberg PD, Gilbert MJ, Riddell SR . Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis Blood 1994 83: 1971–1979
    CAS PubMed Google Scholar
  6. Ljungman P, Plotkin SA . Workshop on CMV disease: definitions, clinical severity scores and new syndromes Scand J Infect Dis 1995 99: (Suppl.) 87–89
    Google Scholar
  7. Halwachs G, Zach R, Pogglitsch H et al. A rapid immunocytochemical assay for CMV detection in peripheral blood of organ-transplanted patients in clinical practice Transplantation 1993 56: 338–342
    Article CAS PubMed Google Scholar
  8. Ljungman P, Bock RD, Cordonnier C et al. Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT Bone Marrow Transplant 1993 12: 399–403
    CAS PubMed Google Scholar
  9. Emanuel D, Cunningham I, Jules-Elysee K et al. Cytomegalovirus pneumonia after bone marrow transplantation succcesfully treaeted with the combination of ganciclovir and high-dose intravenous immune globulin Ann Intern Med 1988 109: 777–782
    Article CAS PubMed Google Scholar
  10. Reed EC, Bowden RA, Dandliker PS et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants Ann Intern Med 1988 109: 783–788
    Article CAS PubMed Google Scholar
  11. Frank I, Friedman HM . Progress in the treatment of cytomegalovirus pneumonia Ann Intern Med 1988 109: 769–771
    Article CAS PubMed Google Scholar
  12. Ljungman P, Cordonnier C, Einsele H et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of EBMT Bone Marrow Transplant 1998 21: 473–476
    Article CAS PubMed Google Scholar
  13. Zaia JA . Pathogenesis of CMV-associated diseases in 1990 Transplant Proc 1991 23: (Suppl. 3) 1–4
    CAS PubMed Google Scholar
  14. Machado CM, Vilas Boas LS, Mendes AV et al. Extended antigenemia surveillance and late CMV infection after allodgeneic BMT San Francisco, California: 39th ICACC 1999 Abstr. 1946
  15. Goodrich JM, Mori M, Gleaves CA et al. Early tratment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation New Engl J Med 1991 325: 1601–1607
    Article CAS PubMed Google Scholar
  16. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp-65 antigenemia-guided early treatment with ganciclovir vs ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study Blood 1996 88: 4063–4071
    CAS PubMed Google Scholar

Download references

Author information

Authors and Affiliations

  1. BMT Program, Fundação Pró Sangue Hemocentro de São Paulo, Discipline of Hematology, São Paulo, Brazil
    CM Machado, FL Dulley, MCA Macedo, RL Silva, R Pallota & RS Saboya
  2. Virology Laboratory of Instituto de Medicina Tropical de São Paulo, São Paulo, Brazil
    CM Machado, LSVilas Boas & CS Pannuti
  3. Pathology Department of INCOR-HC, University of São Paulo Medical School, São Paulo, Brazil
    JB Castelli

Authors

  1. CM Machado
    You can also search for this author inPubMed Google Scholar
  2. FL Dulley
    You can also search for this author inPubMed Google Scholar
  3. LSVilas Boas
    You can also search for this author inPubMed Google Scholar
  4. JB Castelli
    You can also search for this author inPubMed Google Scholar
  5. MCA Macedo
    You can also search for this author inPubMed Google Scholar
  6. RL Silva
    You can also search for this author inPubMed Google Scholar
  7. R Pallota
    You can also search for this author inPubMed Google Scholar
  8. RS Saboya
    You can also search for this author inPubMed Google Scholar
  9. CS Pannuti
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Machado, C., Dulley, F., Boas, L. et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy.Bone Marrow Transplant 26, 413–417 (2000). https://doi.org/10.1038/sj.bmt.1702526

Download citation

Keywords

This article is cited by